Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisdexamfetamine dimesylate
Drug ID BADD_D01299
Description Also known as _Vyvanse_, lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine [A40246]. It is paired with the essential amino acid _L-lysine_. Lisdexamfetamine dimesylate increases attention span and decreases restlessness in children and adults who are overactive/hyperactive, cannot concentrate for long periods, or are easily distracted or impulsive [A2230]. As a central nervous system stimulant, lisdexamfetamine is utilized as an adjunct therapy in the treatment of attention deficit hyperactivity disorder (ADHD). As a prodrug, lisdexamfetamine was specifically engineered as an abuse-resistant product [F2368]. The mechanism by which this occurs is through delayed release after ingestion (unlike some other psychostimulant drugs, which may be abused). After oral administration and absorption, enzyme hydrolysis after contact with red blood cells metabolize lisdexamfetamine into L- lysine, a naturally occurring essential amino acid and active _d-amphetamine_, which is responsible for the drug’s pharmacological effects. Gastrointestinal pH does not affect this conversion, and the addition of the L-lysine slows the amount of d-amphetamine available in the circulation and central nervous system [F2368].
Indications and Usage For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246]. This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
Marketing Status approved; investigational
ATC Code N06BA12
DrugBank ID DB01255
KEGG ID D04747
MeSH ID D000069478
PubChem ID 11597697
TTD Drug ID D00DEF
NDC Product Code 65392-0118; 59417-106; 59116-3011; 61960-0300; 59417-104; 59417-116; 59417-107; 59417-115; 59417-119; 59116-3012; 59417-103; 51634-2058; 59417-102; 17180-1100; 59417-117; 59417-118; 59417-120; 59417-101; 59417-105; 59116-3013; 59116-3010
UNII SJT761GEGS
Synonyms Lisdexamfetamine Dimesylate | Dimesylate, Lisdexamfetamine | Lis-dexamfetamine Dimesylate | Dimesylate, Lis-dexamfetamine | Lis dexamfetamine Dimesylate | Vyvanse | Elvanse | Lisdexamfetamine | NRP104 | NRP-104 | NRP 104
Chemical Information
Molecular Formula C17H33N3O7S2
CAS Registry Number 608137-33-3
SMILES CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.007--Not Available
Tic17.02.05.024; 19.11.04.001--Not Available
Tourette's disorder19.11.04.002; 17.19.02.001; 03.10.01.001--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular hypertrophy02.04.02.012--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Affect lability19.04.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Cardiac disorder02.11.01.003--Not Available
Libido disorder19.08.03.004; 21.03.02.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Dermatillomania23.03.11.011; 19.06.05.005--Not Available
Device stimulation issue27.01.02.005--Not Available
The 3th Page    First    Pre   3    Total 3 Pages